Compare Orchid Chemicals with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs PFIZER - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD PFIZER ORCHID PHARMA LTD/
PFIZER
 
P/E (TTM) x -0.4 39.8 - View Chart
P/BV x 0.1 6.7 1.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA LTD   PFIZER
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
PFIZER
Mar-19
ORCHID PHARMA LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1943,840 5.1%   
Low Rs352,080 1.7%   
Sales per share (Unadj.) Rs276.5455.0 60.8%  
Earnings per share (Unadj.) Rs-79.293.8 -84.5%  
Cash flow per share (Unadj.) Rs-43.5109.4 -39.7%  
Dividends per share (Unadj.) Rs022.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.9658.2 8.2%  
Shares outstanding (eoy) m70.4545.75 154.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.46.5 6.4%   
Avg P/E ratio x-1.431.6 -4.6%  
P/CF ratio (eoy) x-2.627.1 -9.7%  
Price / Book Value ratio x2.14.5 47.2%  
Dividend payout %024.0 0.0%   
Avg Mkt Cap Rs m8,067135,420 6.0%   
No. of employees `0002.82.6 106.4%   
Total wages/salary Rs m2,5273,238 78.0%   
Avg. sales/employee Rs Th6,956.17,911.4 87.9%   
Avg. wages/employee Rs Th902.51,230.9 73.3%   
Avg. net profit/employee Rs Th-1,993.01,630.7 -122.2%   
INCOME DATA
Net Sales Rs m19,47720,815 93.6%  
Other income Rs m4071,674 24.3%   
Total revenues Rs m19,88422,489 88.4%   
Gross profit Rs m1,1035,712 19.3%  
Depreciation Rs m2,519714 352.9%   
Interest Rs m5,22773 7,169.8%   
Profit before tax Rs m-6,2366,599 -94.5%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,309 -5.4%   
Profit after tax Rs m-5,5804,291 -130.1%  
Gross profit margin %5.727.4 20.6%  
Effective tax rate %2.035.0 5.7%   
Net profit margin %-28.720.6 -139.0%  
BALANCE SHEET DATA
Current assets Rs m11,01427,167 40.5%   
Current liabilities Rs m32,0608,917 359.5%   
Net working cap to sales %-108.187.7 -123.2%  
Current ratio x0.33.0 11.3%  
Inventory Days Days9568 139.9%  
Debtors Days Days3430 111.5%  
Net fixed assets Rs m29,4408,862 332.2%   
Share capital Rs m705458 154.0%   
"Free" reserves Rs m2,04329,656 6.9%   
Net worth Rs m3,80030,113 12.6%   
Long term debt Rs m9,01825 36,071.6%   
Total assets Rs m46,51039,400 118.0%  
Interest coverage x-0.291.5 -0.2%   
Debt to equity ratio x2.40 285,859.8%  
Sales to assets ratio x0.40.5 79.3%   
Return on assets %-0.811.1 -6.9%  
Return on equity %-146.914.2 -1,030.7%  
Return on capital %-3.722.1 -16.9%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513428 1,754.2%   
Fx outflow Rs m5,649786 718.3%   
Net fx Rs m1,865-358 -520.7%   
CASH FLOW
From Operations Rs m1,682978 171.9%  
From Investments Rs m-9,860351 -2,807.6%  
From Financial Activity Rs m6,644-1,099 -604.8%  
Net Cashflow Rs m-1,535231 -665.1%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 4.6 7.5 61.3%  
FIIs % 3.3 4.9 67.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 23.7 233.3%  
Shareholders   84,811 85,207 99.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  WYETH LTD  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to trade on a volatile note and ended on a flat note today. At the closing bell, the BSE Sensex stood lower by 24 points (down 0.1%).

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

My Best Trading Ideas When Interest Rates Are So Low(Fast Profits Daily)

Jul 23, 2020

India's interest rates are lower than the inflation rate. Here are the best trades for this situation.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS